Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 5, 1996 - Issue 7
Submit an article Journal homepage
9
Views
5
CrossRef citations to date
0
Altmetric
Original Article

Section Review Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: The pharmaceutical potential of seleno-organic compounds

Michael J. Parnham Parnham Advisory Services (PAS), Von Guericke Allee 4, D-53125, Bonn; Pharmakologisches Institut für Naturwissenschaftler, Goethe-Universität, Frankfurt/M, Germany
Pages 861-870 | Published online: 03 Mar 2008

References to Primarv Literature

  • VARO P, ALETHAN G, EKHOLM P, ARO A, KOIVISTOINEN P: Selenium intake and serum selenium in Finland: effects of soil fertilization with selenium. Am. J. Clin. Nutr. (1988) 48:324–329.
  • MATSON EJ: Selenium sulfide as an antidandruff agent. J. Soc. Cosine!. Chem. (1956) 7:459–466.
  • KLAYMAN DL: Selenium compounds as potential chemotherapeutic agents. In: Organic Selenium Com-pounds. Their Chemistry and Biology. Klayman DL, Giinther WH (Eds.), John Wiley and Sons, New York (1973):727–761.
  • SHAMBERGER RJ: Synthetic forms of selenium and their chemotherapeutic uses. In: Biochemistry of Selenium, Shamberger RJ (Ed.), Plenum Press, New York (1983):273–310.
  • PARNHAM MJ, GRAF E: Pharmacology of synthetic or-ganic selenium compounds. Prog. Drug Res. (1991) 36:9–47.
  • KOLLER LD, EXONThe two faces of selenium - deficiency and toxicity - are similar in animals and man. Can.1 Vet. Res. (1986) 50:297–306.
  • ROTRUCK JT: Discovery of the role of selenium in glutathione peroxidase. In: Selenium in Biology and Medi-cine. Spallholz JE, Martin JL, Ganther HE (Eds.), Avi Publish-ing Co., Westport (1981):10–16.
  • CADENAS E, SIES H: Oxidative stress: excited oxygen species and enzyme activity. Adv. Enz. Regul. (1985) 23:217–237.
  • URSINI F, BINDOLI A: The role of selenium peroxidases in the protection against oxidative damage of mem-branes. Chem. Phys, Lipids (1987) 44:255–276.
  • SRIVASTAVA PC, PICKERING MV, ALLEN LB et al.: Synthe-sis and antiviral activity of certain thiazole C-nucleo-sides. J. Med. Chem. (1977) 20:256–262.
  • SRIVASTAVA PC, ROBINS RK: Synthesis and antitumor activity of 2-13D-ribofuranosyl-selenazole-4-carbox-amide and related derivatives. J. Med. Chem. (1983) 26:445–448.
  • STREETER DG, ROBINS RK: Comparative in vitro studiesof tiazofurin and a selenazole analog. Biochem. Biophys. Res. Commun. (1983) 115:54–50.
  • BORITZKI TJ, BERRY DA, BESSERER JA et al.: Biochemical and antitumor activity of tiazof-urin and its selenium analog (2-beta-D-ribofuranosylselenazole-4-carbox- amide). Biochem. Phannacol. (1985) 34:1109–1114.
  • KIRSID, NORTH JA, MCKERMAN PA et al.: Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent. Antimicrob. Agents Chem other. (1983) 24:353–361.
  • MEDINA D, MORRISON DG: Current ideas on seleniumas a chemopreventive agent. Patbol. Immunopathol. Res. (1988) 7:187–199.
  • BLOT WJ, LI JY, TAYLOR PR et al.: Nutrition interventiontrials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence and disease-specific mortality in the general population. J. Natl. Cancer. Inst. (1993) 85:1483–1492.
  • IP C, GANTHER HE: Relationship between the chemical form of selenium and anticarcinogenic activity. In: Cancer Cbemoprevention. Wattenberg L, Boone CW, Kelloff GJ (Eds.), CRC Press, Boca Raton, Fl (1992):479–488.
  • NEVE J: Sélénium et pathologic cardiovasculaire. Path. Biol. (1989) 37: 1102–1106.
  • GE K, XUE A, BAI J, WANG S: Keshan disease - an endemiccardiomyopathy in China. Virch. Arch. Patbol. Anat. (1983) 401:1–15.
  • REJHOLEC V: Selenofen. Drugs of the Future (1985) 10:572.
  • POLLOCK SG, HERMANN HH, FOWLER LC et al.: Demon-stration of the antihypersensive activity of pheny1-2-aminoethyl selenide. J. Pharmacol. Exp. Ther. (1988) 246:227–234.
  • SIES H: Ebselen, a selenoorganic compound as glu-tathione peroxide mimic. Free Rad. Biol. Med. (1993) 14:313–323.
  • MAIORINO M, ROVERI A, URSINI F: Antioxidant effect ofebselen (PZ51): peroxidase mimetic activity on phos-pholipid and cholesterol hydroperoxides vs. free radi-cal scavenger activity. Arch. Biochem. Biophys. (1992) 295:404–409.
  • SCHEWE T: Molecular actions of ebselen - an antlinflam-matory antioxidant. Gen. Pharmac. (1995) 26:1153–1169.
  • ZEMBOWICZ A, HATCHETT RJ, RADZISZEWSKI W, GRY-GLEWSKI RJ: Inhibition of endothelial nitric oxide syn-thase by ebselen. Prevention by thiols suggests the Inactivation of ebselen of a critical thiol essential for the catalytic activity of nitric oxide synthase./ Pbarma-col. Exp. Ther. (1993) 267:1112–1118.
  • HATTORI R, INOUE R, SASE K et al.: Preferential inhibi-tion of inducible nitric oxide synthase by ebselen. Eur. Pharmaca (1994) 267:R1–R2.
  • HUTHER AM, ZHANG Y, SAUER A, PARNHAM MJ: Anti-malarial properties of ebselen. Parasitol. Res. (1989) 75:353–360.
  • WENDEL A, FAUSEL M, SAFAYHI H, 'mos G, OTTER R: Anovel biologically active seleno-organic compound - II. Activity of PZ 51 in relation to glutathione peroxidase. Biochem. Pharmacol. (1984) 33:3241–3245.
  • FARNHAM MJ, LEYCK S, GRAF E, DOWLING EJ, BLAKE DR:The pharmacology of ebselen. Agents and Actions (1991) 32:4–9.
  • GRIFFITH HR, DOWLING EJ, SAHINOGLU T et al.: Theselective protection afforded by ebselen against lipid peroxidation in an ROS-dependent model of inflamma-tion. Agents and Actions (1992) 36:107–111.
  • WENDEL A, TIEGS G: A novel biologically active seleno-organic compound VI. Protection by ebselen (P251) against galactosamide/endotoxin-induced hepatitis in mice. Biochem. Pharmacol. (1986) 35:2115–2118.
  • HARTUNG HP, SCHAEFER B, HEININGER K, TOYKA ICV:Interference with arachidonic acid metabolism sup-presses experimental allergic neuritis. Ann. Neurol. (1986) 20:168,
  • SCHALKWIJK J, VAN DEN BERG 'WS, VAN DE PUTTE LBA,JOOSTEN LAB: An experimental model for hydrogen peroxide-induced tissue damage. Effects of a single Inflammatory mediator on (peri)articular tissues. Ar-thritis Rheum. (1986) 29:532–538.
  • VAN DYKE TE, BRASWELL L, OFEENBACHER S: Inhibitionof gingivitis by topical application of ebselen and ros-marinic add. Agents and Actions (1986) 19:376–377.
  • TANAKA J, YAMADA F: Ebselen (PZ51) inhibits the for-mation of ishemic brain edema. In: Selenium in Biology and Medicine. Wendel A (Ed.), Springer-Verlag, Heidelberg (1989): 173–176.
  • LEYCK S, PARNHAM MJ: Acute inflammatory and gastriceffects of the seleno-organic compound ebselen. Agents and Actions (1990) 30:425–431.
  • BEIL W, STAAR U, SEWING ICF: Interaction of the anti-in-flammatory seleno-organic compound ebselen with acid secretion in isolated parietal cells and gastric ITVIC"-ATPase. Biochem. Pharmacol. (1990) 40:1997–2003.
  • UEDA 5, YOSHIKAWA T, TAICAHASHI S et al.: Protectionby seleno-organic compound, ebselen, against acute gastric mucosal injury induced by ischemia-reperfu-sion in rats. Adv. Exp. Med. Biol. (1990) 1264:187–190.
  • GOWER JD, BALDOCK R, SULLIVAN AM et al.: Protectionagainst endotoxin induced foetal resoption in mice by desferrioxamIne and ebselen. Int. J. Exp. Pathol. (1990) 71:433–440.
  • BALDEW CS, MCVIE JG., VAN DER VALK MA et al.: Selectivereduction of cis-diaminedi-chloroplatinum(II) nephro-toxicity by ebselen. Cancer Res. (1990) 50:7031–7036.
  • FLECHNER I, MARUTA K, BURKART V et al.: Effects ofradical scavengers on the development of experimental diabetes. Diabetes Res. (1990) 13:67–73.
  • JOHSHITA H, SASAIU T, MATSUI T et al.: Effects of ebselen (PZ51) on ischemic brain edema after local ischemia in cats. Acta Neurochir. (1990) 51(Suppl.):239–241.
  • DAWSON DA, MASAYASU H, GRAHAM DI, MACRAE IM: The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by tran-sient focal cerebral ischaemia in the rat. Neurosci. Lett. (1995) 185:65–69.
  • SAITO I, ABE E, YOSHIMOTO T et al.: Multicenter ran-domized clinical trial of ebselen in patients with aneu-rysmal subarachnold hemorrhage. J. Cereb. Blood Flow Metab. (1995) 15\(Suppl. 1):S162.
  • NIEDERAU C, UDE K, NIEDERAU M et al.: Effects of the seleno organic substance ebselen in two different mod-els of acute pancreatitis. Pancreas (1991) 6:282–290.
  • GOWER JD, LANE NJ, GODDARD G et al.: Ebselen. Anti-oxidant capacity in renal preservation. Biochem. Phar-macol. (1992) 43:2341–2348.
  • BEIL W, STAAR U, SEWING K-F: Interaction of the anti-inflammatory seleno-organic compound ebselen with add secretion in isolated parietal cells and gastric 11411e-ATPase. Biochem. Pharmacol. (1990) 40:1997–2003.
  • TABUCHI Y, KUREBAYASHI Y: Antisecretory and antiul-cer effects of ebselen, a seleno-organic compound, in rats. Jpn. J. Pharrnacol. (1993) 61:255–257.
  • TABUCHI Y, OGASAWARA T, FURUHAMA K: Mechanism of the inhibition of hog gastric 11111{+-ATPase by the seleno-organic compound ebselen. Arzneim.-Forsch./ Drug Res. (1994) 44:51–54.
  • PARNHAM MJ, BIEDERMANN J, BITTNER C et al.: Structureactivity relationships of a series of anti-inflammatory benzisoseknazolones (BISAs). Agents Actions (1989) 27:306–308.
  • COTGREAVE IA, MOLDEUS P, BRATTSAND R et al.: a-(Phenylselenypacetophenone derivatives with g,lu-tathione peroxidase-like activity. Biochem. Pharmacol. (1992) 43:793–802.
  • MLOCHOWSKI J, KLOC K, SYPER L, INGLOT A, PIASECKIE: Aromatic and azaaromatic diselenides, benzisosek-nazolones and related compounds as immunomodula-tors active in humans: synthesis and properties. Lie bigs Ann. Chem. (1993):1239–1244.
  • ARNER EC, WRIGHT SW, PRATTA MA: Isothiazolones Inhibit cartilage degradation by interfering with pros-tromelysin activation. 7th Int. Conf Infiam. Res. Assoc. White Haven, PA (1994):W12.
  • HLASTA DJ, ACKERMAN JH, COURT JJ et al.: A novel classof cyclic 13-dkarbonyl leaving groups and their use in the design of benzisothiazolone human leucocyte eleas-tase inhibitors. J. Med. Chem. (1995) 38:4687–4692.
  • HATCHETT RJ, GRYGLEWSKI RJ, MLOCHOWSKI J, ZEM-BOWICZ A, RADZISZEWSKI W: Carboxyebselen a potent and selective inhibitor of endothelial nitric oxide syn-thase. J. Physiol. Pharmacot (1994) 45:55–67.
  • FARNHAM MJ, DOWLING EJ, BROQUET C, BRAQUET P: Seleno-organic compounds as potential pharmaceuti-cals. In: Uses of Selenium and Tellurium. Carapella SC, Oldfield JE, Palmieri Y (Eds.), Selenium-Tellurium Develop-ment Assoc., Grimbergen, Belgium (1994):75–80.
  • BURK RF, HILL KE: Regulation of selenoproteins. Ann.Rev. Nutr. (1993) 13:65–81.
  • KIM DK, KIM HT, KIM KH, SHIN YO: Potent and selectiveinhibition of HIV-1 replication by novel 6-substituted pyrimicline derivatives. 34th ICAACMeeting (4–7 October, I 994):P194.
  • INGLOT AD, MLOCHOWSKI J, ZIELINSKA-JENCZYLIK J et al.: Seleno-organic compounds as immunosticHnulants: an approach to the structure-activity relationship. Arch. Immunot Ther. Exp. (1996) 44:67–75.
  • BECK MA, SHI Q, MORRIS VC, LEVANDER OA: Rapid genomic evolution of a non-virulent coxackievirus B3 In selenium-deficient mice results in selection of iden-tical virulent isolates. Nature Medicine (1995) 1:433–436.

References to Primarv Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.